ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1387

Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis
Abstract Number: 0181

Magnetic Resonance Imaging Findings in Early Rheumatoid Arthritis: Are There Differences Based on Autoantibody Status?
Abstract Number: 1285

Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Abstract Number: 0765

Male Juvenile Systemic Sclerosis Patients Have More Severe Disease: Results from the International Juvenile Scleroderma Inception Cohort
Abstract Number: 1940

Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Abstract Number: 1481

Malondialdehyde-acetaldehyde Antibodies Occur in Systemic Lupus Erythematosus and Associate Specifically with Neuropsychiatric Involvement
Abstract Number: 0950

Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/Racemosa
Abstract Number: 1004

Manipulation of B7 Family Member Expression Demonstrates Synovial Macrophage Plasticity and Possible Future Targets for Treatment of Rheumatoid Arthritis
Abstract Number: 1672

Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
Abstract Number: 1166

Marijuana Use Amongst Rheumatology Patients: It’s More Common Than Rheumatologists Believe
Abstract Number: 0716

Marked Capillary Basement Membrane Reduplication Is the Hallmark Histopathological Feature of Scleromyositis
Abstract Number: 0280

Mast Cells Contribute to the Development of Lung Fibrosis via Inducing Myofibroblast Differentiation by TGF-β Production
Abstract Number: 0236

Maternal Attachment, Anxiety and Depressive Symptoms in Pregnant Women with Rheumatic Diseases
Abstract Number: 0005

Maturation and Dysfunction of Autoreactive B Cell Clones in Tissues of Patients with Sjögren’s Syndrome
Abstract Number: 0713

MDA5 Helicase Domains Identified as the Main Targets of Anti-MDA5 Autoantibodies in European Dermatomyositis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].